N/A N=7 Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus
Peptic Ulcer
Primary: Number of Participants Completing Natural Orifice Translumenal Endoscopic Surgical (NOTES) Repair — 2; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=483 LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Head and Neck Neoplasms · Carcinoma, Squamous Cell
Primary: Progression-free Survival (PFS) Based on Central Independent Review — 2.63; 1.74 months — p=0.0257
N/A N=1 Treatment With Intravitreal Avastin for Large Uveal Melanomas
Uveal Melanoma
Primary: The Response of Intravitreal Avastin in Causing a Clinically Significant Reduction in Uveal Melanoma Tumor Size (Base Height and Volume). — 1; 0; 0; 0 participants
Phase 2 N=156 Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Maximum Tolerated of Sunitinib Combined With Cisplatin and Etoposide (Phase I) — 25 mg/day
N/A N=40 Low-dose IL-2( Interleukin-2) Treatment in SLE
Systemic Lupus Erythematosus
Primary: Number of Participants Who Were SLE Responders (SRI) — 12; 27; 33; 34 participants
Phase 3 N=152 Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
Pediatric Glaucoma · Elevated IOP in Pediatric Patients · Ocular Hypertension in Pediatric Patients
Primary: Mean Change From Baseline in IOP at Month 3 — -5.4; -5.3 mmHg
Phase 3 N=105 A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis
Chronic Sinusitis
Primary: Percentage of Sinuses Requiring Post-operative Intervention — 33.3; 46.9 percentage of sinuses — p=0.0280
N/A N=97 Effective Treatments for Jellyfish Stings
Jellyfish Stings
Primary: Mean Change in Pain in the Treated Human Arm (Not Placebo) From Baseline Determined by Measures (17) Taken Over 24 Hours — 0.13; -0.19; -0.46; -0.31 units on a scale
Phase 2 N=46 Effectiveness of Acupuncture in Relieving Pain Due to Fibromyalgia
Fibromyalgia
Primary: Change in Mu-opioid Receptor Occupancy — 0.2352; .0015 Unitless: binding potential is Bmax/Kd
Phase 2 N=21 Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
Mantle Cell Lymphoma · Lymphoma
Primary: Response Rate — 52; 0; 19; 5 percentage of participants
N/A N=4,199 TAXUS Libertē Post Approval Study
Coronary Artery Disease
Primary: Cardiac Death or Myocardial Infarction — 2.1 percentage of participants
Phase 2 N=240 Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy
Allergic Rhinitis · Rhinoconjunctivitis
Primary: Combined Rhinoconjunctivitis Symptom and Medication Score — 0.86; 0.64; 0.72 score (maximum=3)
Phase 3 N=88 Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery
Breast Cancer
Primary: Proportion of Participants With No Pain Immediately After Surgery
Phase 2 N=179 Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 1.4; 3.0 months — p=<0.0001
Phase 4 N=86 Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Nocturnal IOP at Week 4 — 24.2; 23.6; 18.6; 18.9 mmHg